{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-020827","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.700610+00:00","generated_at":"2026-06-02T17:47:43.497706+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"X4 Pharma reports Q1 net loss of $51.8M; XOLREMDI approved for WHIM syndrome","bullets":["Net loss $51.8M vs $24.0M in Q1 2023; includes $13.8M non-cash loss on warrant liability.","Cash, equivalents, and securities $81.6M as of Mar 31, 2024; runway into 2025 excluding PRV monetization.","FDA approved XOLREMDI (mavorixafor) for WHIM syndrome in patients 12+ in late April 2024; U.S. launch underway.","Phase 2 interim data for mavorixafor in chronic neutropenia expected June 2024; Phase 3 trial planned in Q2 2024.","SG&A expenses rose to $17.4M from $7.2M due to commercial launch preparations."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-020827","json":"https://secwatch.observer/filing/0001628280-24-020827.json","markdown":"https://secwatch.observer/filing/0001628280-24-020827.md","text":"https://secwatch.observer/filing/0001628280-24-020827.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024020827/0001628280-24-020827-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024020827/xfor-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T17:47:43.497706+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d123321ebfa194caba7b3c1802b49a67fa7c529","claim":"X4 Pharmaceuticals, Inc reported for the first quarter ended March 31, 2024 results: net income $51.8 million.","evidence_excerpt":"X4 reported a net loss of $51.8 million for the first quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024020827/0001628280-24-020827-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the first quarter ended March 31, 2024"},{"label":"Net income","value":"$51.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}